Next 12 months will see two of our Tier 1 products finishing their phase 3 trials .. CHF later in 2019 and CLBP in first half of 2020.
First product for aGVHD will be up for approval with the FDA early 2020.
GI Bleeding accelerated approval on the cards for late 2019 or early 2020.
RA likely to be partnered, so a phase 2b trial can progress.
JCR partner in Japan continuing to expand product label.
Chinese Partner Tasly to start regulatory approval in China for MSC 150IM.
We are talking months now, not years.
MSB Trading - 2019, page-1128
-
- There are more pages in this discussion • 3,297 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5460 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 978 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |